AstraZeneca’s COVID vaccine faces new round of restrictions—even after the EMA’s renewed backing
Several countries stopped using AstraZeneca's COVID-19 shot earlier this month after reports of rare blood…
15 million Johnson & Johnson coronavirus vaccines ruined due to human error: NYT
Johnson & Johnson's COVID-19 vaccine rollout has been slower than expected in the U.S., with just…
AstraZeneca COVID-19 vaccine gets new Vaxzevria name, but is it enough to overcome rollout imbroglio?
AstraZeneca’s COVID-19 vaccine has an official name, Vaxzevria, now approved in Europe. But is a new…
Pumped by a big year for its flu shots, Sanofi lays out €600M for new vaccine manufacturing plant
Sanofi may not be at the forefront in COVID-19 vaccines, but in influenza, it's the…
Johnson & Johnson vaccine partner Emergent still lacks FDA’s manufacturing green light
The U.S. manufacturing partner turning out drug substance for Johnson & Johnson's single-dose COVID-19 vaccine…
Moderna CEO Bancel snags close to $13M in 2020 pay, thanks to COVID-19 vaccine work
Moderna entered 2020 a clinical-stage biotech with messenger RNA on the brain. Now, the company…
TikTok famous? Pfizer, Moderna, J&J and AZ shoutouts on social media boost vaccine credibility—and pharmas’ image
A man in a Pfizer sweater sits down in waiting room, notices another man in…
MorphoSys, Incyte are touting Monjuvi’s potential down the line—but COVID-19 is slowing its launch now
To hear MorphoSys CEO Jean-Paul Kress tell it, the company and partner Incyte have a…
Pfizer partner BioNTech, riding high on COVID-19 vaccine launch, eyes $11.5B in revenue this year
Pfizer and BioNTech have hustled to produce as many COVID-19 vaccine doses as possible this year,…
Johnson & Johnson pledges 400M single-dose COVID-19 vaccines to African Union
Johnson & Johnson has kept global access at the heart of its COVID-19 vaccine supply…